TABLE OF CONTENTS
1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA RADIOTHERAPY MARKET 36
1.4 CURRENCY AND PRICING 38
1.5 LIMITATIONS 38
1.6 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
2.1 MARKETS COVERED 41
2.2 GEOGRAPHICAL SCOPE 42
2.3 YEARS CONSIDERED FOR THE STUDY 43
2.4 DBMR TRIPOD DATA VALIDATION MODEL 44
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.6 MULTIVARIATE MODELLING 48
2.7 PRODUCT AND SERVICES SEGMENT LIFELINE CURVE 49
2.8 MARKET END USERS COVERAGE GRID 50
2.9 DBMR MARKET POSITION GRID 51
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
4.1 PESTLE ANALYSIS 57
4.2 PORTER'S FIVE FORCES MODEL 58
4.3 PRICING ANALYSIS 59
5 REGULATORY GUIDELINES FOR RADIOTHERAPY 61
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING PREVALENCE OF CANCER DISEASE 66
6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 66
6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 67
6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 67
6.2 RESTRAINTS 67
6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 67
6.2.2 HIGH COST OF TREATMENT AND RADIOTHERAPY PROCEDURE 68
6.3 OPPORTUNITIES 68
6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 68
6.3.2 GROWING GOVERNMENT INITIATIVES TOWARD CANCER TREATMENT 69
6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 70
6.4 CHALLENGES 70
6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 70
6.4.2 RISK OF RADIATION EXPOSURE 71
7 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY PRODUCT & SERVICES 72
7.1 OVERVIEW 73
7.2 SERVICES 75
7.3 PRODUCT 75
7.4 SOFTWARE 75
8 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY TYPE 76
8.1 OVERVIEW 77
8.2 EXTERNAL-BEAM RADIATION THERAPY 79
8.3 INTERNAL RADIATION THERAPY 79
8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 79
8.5 OTHERS 79
9 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY APPLICATION 80
3.1 OVERVIEW 81
9.1 BREAST CANCER 84
9.2 LUNG CANCER 84
9.3 PROSTATE CANCER 84
9.4 COLORECTAL CANCER 84
9.5 LYMPHOMA 84
9.6 LIVER CANCER 84
9.7 THYROID CANCER 84
9.8 BRAIN CANCER 84
9.9 CERVICAL CANCER 85
9.10 SPINE CANCER 85
9.11 OTHERS 85
10 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY END USER 86
10.1 OVERVIEW 87
10.2 HOSPITALS 89
10.3 RADIATION THERAPY CENTERS 89
10.4 SPECIALTY CLINICS 89
10.5 OTHERS 89
11 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 90
11.1 OVERVIEW 91
11.2 DIRECT TENDERS 93
11.3 THIRD PARTY DISTRIBUTORS 93
11.4 OTHERS 93
12 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET, BY REGION 94
12.1 MIDDLE EAST AND AFRICA 95
13 MIDDLE EAST & AFRICA RADIOTHERAPY MARKET: COMPANY LANDSCAPE 147
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 147
14 SWOT ANALYSIS 148
15 COMPANY PROFILE 149
15.1 SIEMENS HEALTHCARE GMBH 149
15.1.1 COMPANY SNAPSHOT 149
15.1.2 REVENUE ANALYSIS 149
15.1.3 COMPANY SHARE ANALYSIS 150
15.1.4 PRODUCT PORTFOLIO 150
15.1.5 RECENT DEVELOPMENT 150
15.2 ELEKTA 151
15.2.1 COMPANY SNAPSHOT 151
15.2.2 REVENUE ANALYSIS 151
15.2.3 COMPANY SHARE ANALYSIS 152
15.2.4 PRODUCT PORTFOLIO 152
15.2.5 RECENT DEVELOPMENTS 152
15.3 GENERAL ELECTRIC COMPANY 153
15.3.1 COMPANY SNAPSHOT 153
15.3.2 REVENUE ANALYSIS 153
15.3.3 COMPANY SHARE ANALYSIS 154
15.3.4 PRODUCT PORTFOLIO 154
15.3.5 RECENT DEVELOPMENT 154
15.4 HITACHI, LTD. 155
15.4.1 COMPANY SNAPSHOT 155
15.4.2 REVENUE ANALYSIS 155
15.4.3 PRODUCT PORTFOLIO 156
15.4.4 RECENT DEVELOPMENT 156
15.5 KONINKLIJKE PHILIPS N.V. 157
15.5.1 COMPANY SNAPSHOT 157
15.5.2 REVENUE ANALYSIS 157
15.5.3 COMPANY SHARE ANALYSIS 158
15.5.4 PRODUCT PORTFOLIO 158
15.5.5 RECENT DEVELOPMENT 158
15.6 ACCURACY INCORPORATED 159
15.6.1 COMPANY SNAPSHOT 159
15.6.2 REVENUE ANALYSIS 159
15.6.3 PRODUCT PORTFOLIO 160
15.6.4 RECENT DEVELOPMENT 160
15.7 BEBIG MEDICAL. 161
15.7.1 COMPANY SNAPSHOT 161
15.7.2 PRODUCT PORTFOLIO 161
15.7.3 RECENT DEVELOPMENT 161
15.8 BRAINLAB AG 162
15.8.1 COMPANY SNAPSHOT 162
15.8.2 PRODUCT PORTFOLIO 162
15.8.3 RECENT DEVELOPMENTS 162
15.9 CANON MEDICAL SYSTEMS CORPORATION 163
15.9.1 COMPANY SNAPSHOT 163
15.9.2 REVENUE ANALYSIS 163
15.9.3 PRODUCT PORTFOLIO 164
15.9.4 RECENT DEVELOPMENT 164
15.10 ECKERT & ZIEGLER BEBIG 165
15.10.1 COMPANY SNAPSHOT 165
15.10.2 REVENUE ANALYSIS 165
15.10.3 PRODUCT PORTFOLIO 166
15.10.4 RECENT DEVELOPMENT 166
15.11 IBA WORLDWIDE 167
15.11.1 COMPANY SNAPSHOT 167
15.11.2 REVENUE ANALYSIS 167
15.11.3 PRODUCT PORTFOLIO 168
15.11.4 RECENT DEVELOPMENT 168
15.12 LINATECH INC 169
15.12.1 COMPANY SNAPSHOT 169
15.12.2 PRODUCT PORTFOLIO 169
15.12.3 RECENT DEVELOPMENT 169
15.13 MEVION MEDICAL SYSTEMS 170
15.13.1 COMPANY SNAPSHOT 170
15.13.2 PRODUCT PORTFOLIO 170
15.13.3 RECENT DEVELOPMENT 170
15.14 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 171
15.14.1 COMPANY SNAPSHOT 171
15.14.2 PRODUCT PORTFOLIO 171
15.14.3 RECENT DEVELOPMENT 171
15.15 P-CURE 172
15.15.1 COMPANY SNAPSHOT 172
15.15.2 PRODUCT PORTFOLIO 172
15.15.3 RECENT DEVELOPMENT 172
15.16 SHINVA MEDICAL INSTRUMENT CO., LTD. 173
15.16.1 COMPANY SNAPSHOT 173
15.16.2 PRODUCT PORTFOLIO 173
15.16.3 RECENT DEVELOPMENT 173
15.17 UNITED IMAGING HEALTHCARE CO., LTD 174
15.17.1 COMPANY SNAPSHOT 174
15.17.2 PRODUCT PORTFOLIO 174
15.17.3 RECENT DEVELOPMENT 174
15.18 VIEWRAY TECHNOLOGIES, INC. (VIEWRAY) 175
15.18.1 COMPANY SNAPSHOT 175
15.18.2 REVENUE ANALYSIS 175
15.18.3 PRODUCT PORTFOLIO 176
15.18.4 RECENT DEVELOPMENT 176
15.19 ZEISS INTERNATIONAL 177
15.19.1 COMPANY SNAPSHOT 177
15.19.2 REVENUE ANALYSIS 177
15.19.3 COMPANY SHARE ANALYSIS 178
15.19.4 PRODUCT PORTFOLIO 178
15.19.5 RECENT DEVELOPMENT 178
16 QUESTIONNAIRE 179
17 RELATED REPORTS 183

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.